Trial Profile

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CV 301 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folic acid; Oxaliplatin
Indications Colorectal cancer; Liver metastases
Focus Therapeutic Use

Most Recent Events

18 Apr 2024 Planned End Date changed from 1 Jun 2023 to 31 Dec 2024.
21 Jan 2023 Status changed to discontinued , according to Results presented at the 2023 Gastrointestinal Cancers Symposium
21 Jan 2023 Preliminary efficacy and correlative results presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com